|
1
|
Cancer Genome Atlas N: Cancer Genome Atlas
Network: Comprehensive molecular portraits of human breast tumours.
Nature. 490:61–70. 2012. View Article : Google Scholar
|
|
2
|
Osborne CK and Schiff R: Mechanisms of
endocrine resistance in breast cancer. Annu Rev Med. 62:233–247.
2011. View Article : Google Scholar
|
|
3
|
Osborne CK and Osborne CK: Tamoxifen in
the treatment of breast cancer. N Engl J Med. 339:1609–1618. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Riggins RB, Schrecengost RS, Guerrero MS
and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett.
256:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
García-Becerra R, Santos N, Díaz L and
Camacho J: Mechanisms of resistance to endocrine therapy in breast
cancer: Focus on signaling pathways, miRNAs and genetically based
resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar
|
|
6
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Britton DJ, Hutcheson IR, Knowlden JM,
Barrow D, Giles M, McClelland RA, Gee JM and Nicholson RI:
Bidirectional cross talk between ERalpha and EGFR signalling
pathways regulates tamoxifen-resistant growth. Breast Cancer Res
Treat. 96:131–146. 2006. View Article : Google Scholar
|
|
8
|
Gutierrez MC, Detre S, Johnston S, Mohsin
SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M:
Molecular changes in tamoxifen-resistant breast cancer:
Relationship between estrogen receptor, HER-2, and p38
mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dumont JA, Bitonti AJ, Wallace CD, Baumann
RJ, Cashman EA and Cross-Doersen DE: Progression of MCF-7 breast
cancer cells to antiestrogen-resistant phenotype is accompanied by
elevated levels of AP-1 DNA-binding activity. Cell Growth Differ.
7:351–359. 1996.PubMed/NCBI
|
|
10
|
Mandlekar S, Yu R, Tan TH and Kong AN:
Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling
pathways in tamoxifen-induced apoptosis of human breast cancer
cells. Cancer Res. 60:5995–6000. 2000.PubMed/NCBI
|
|
11
|
Theodosiou A and Ashworth A: MAP kinase
phosphatases. Genome Biol. 3:S30092002. View Article : Google Scholar
|
|
12
|
Camps M, Nichols A and Arkinstall S: Dual
specificity phosphatases: A gene family for control of MAP kinase
function. FASEB J. 14:6–16. 2000.PubMed/NCBI
|
|
13
|
Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee
MK, Choi CS, Neufer PD, Shulman GI, Kim JK and Bennett AM: Mice
lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity
and resistance to diet-induced obesity. Cell Metab. 4:61–73. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Q, Wang X, Nelin LD, Yao Y, Matta R,
Manson ME, Baliga RS, Meng X, Smith CV, Bauer JA, et al: MAP kinase
phosphatase 1 controls innate immune responses and suppresses
endotoxic shock. J Exp Med. 203:131–140. 2006. View Article : Google Scholar
|
|
15
|
Wancket LM, Frazier WJ and Liu Y:
Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology,
physiology, and disease. Life Sci. 90:237–248. 2012. View Article : Google Scholar :
|
|
16
|
Li M, Zhou JY, Ge Y, Matherly LH and Wu
GS: The phosphatase MKP1 is a transcriptional target of p53
involved in cell cycle regulation. J Biol Chem. 278:41059–41068.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sánchez-Pérez I, Martínez-Gomariz M,
Williams D, Keyse SM and Perona R: CL100/MKP-1 modulates JNK
activation and apoptosis in response to cisplatin. Oncogene.
19:5142–5152. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Xu J, Zhou JY, Liu Y and Wu GS:
Mitogen-activated protein kinase phosphatase-1 is required for
cisplatin resistance. Cancer Res. 66:8870–8877. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Small GW, Shi YY, Higgins LS and Orlowski
RZ: Mitogen-activated protein kinase phosphatase-1 is a mediator of
breast cancer chemoresistance. Cancer Res. 67:4459–4466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Zhou JY, Kanakapalli D, Buck S, Wu
GS and Ravindranath Y: High level of mitogen-activated protein
kinase phosphatase-1 expression is associated with cisplatin
resistance in osteosarcoma. Pediatr Blood Cancer. 51:754–759. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brünner N, Frandsen TL, Holst-Hansen C,
Bei M, Thompson EW, Wakeling AE, Lippman ME and Clarke R:
MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer
variant that retains sensitivity to the steroidal antiestrogen ICI
182,780. Cancer Res. 53:3229–3232. 1993.PubMed/NCBI
|
|
22
|
Takeuchi K, Shin-ya T, Nishio K and Ito F:
Mitogen-activated protein kinase phosphatase-1 modulated JNK
activation is critical for apoptosis induced by inhibitor of
epidermal growth factor receptor-tyrosine kinase. FEBS J.
276:1255–1265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mandlekar S and Kong AN: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bogush T, Dudko E, Bogush E, Polotsky B,
Tjulandin S and Davydov M: Tamoxifen non-estrogen receptor mediated
molecular targets. Oncol Rev. 6:e152012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Madeo A, Vinciguerra M, Lappano R, Galgani
M, Gasperi-Campani A, Maggiolini M and Musti AM: c-Jun activation
is required for 4-hydroxytamoxifen-induced cell death in breast
cancer cells. Oncogene. 29:978–991. 2010. View Article : Google Scholar
|
|
26
|
Wang N, Li Z, Tian F, Feng Y, Huang J, Li
C and Xie F: PKCα inhibited apoptosis by decreasing the activity of
JNK in MCF-7/ADR cells. Exp Toxicol Pathol. 64:459–464. 2012.
View Article : Google Scholar
|
|
27
|
Chen P, Li J, Barnes J, Kokkonen GC, Lee
JC and Liu Y: Restraint of proinflammatory cytokine biosynthesis by
mitogen-activated protein kinase phosphatase-1 in
lipopolysaccharide-stimulated macrophages. J Immunol.
169:6408–6416. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao Q, Shepherd EG, Manson ME, Nelin LD,
Sorokin A and Liu Y: The role of mitogen-activated protein kinase
phosphatase-1 in the response of alveolar macrophages to
lipopolysaccharide: Attenuation of proinflammatory cytokine
biosynthesis via feedback control of p38. J Biol Chem.
280:8101–8108. 2005. View Article : Google Scholar
|
|
29
|
Obrero M, Yu DV and Shapiro DJ: Estrogen
receptor-dependent and estrogen receptor-independent pathways for
tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J
Biol Chem. 277:45695–45703. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang HY, Cheng Z and Malbon CC:
Overexpression of mitogen-activated protein kinase phosphatases
MKP1, MKP2 in human breast cancer. Cancer Lett. 191:229–237. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rojo F, González-Navarrete I, Bragado R,
Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C,
Servitja S, Rodriguez-Fanjul V, et al: Mitogen-activated protein
kinase phosphatase-1 in human breast cancer independently predicts
prognosis and is repressed by doxorubicin. Clin Cancer Res.
15:3530–3539. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Zhou JY and Wu GS: ERK-dependent
MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Cancer Res. 67:11933–11941. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rabenoelina F, Semlali A, Duchesne MJ,
Freiss G, Pons M and Badia E: Effect of prolonged hydroxytamoxifen
treatment of MCF-7 cells on mitogen activated kinase cascade. Int J
Cancer. 98:698–706. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Creighton CJ, Hilger AM, Murthy S, Rae JM,
Chinnaiyan AM and El-Ashry D: Activation of mitogen-activated
protein kinase in estrogen receptor alpha-positive breast cancer
cells in vitro induces an in vivo molecular phenotype of estrogen
receptor alpha-negative human breast tumors. Cancer Res.
66:3903–3911. 2006. View Article : Google Scholar : PubMed/NCBI
|
